Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac
Open Access
- 1 February 2009
- journal article
- Published by Informa UK Limited in Clinical Ophthalmology
- Vol. 3, 219-226
- https://doi.org/10.2147/opth.s4820
Abstract
Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac Guadalupe Cervantes-Coste, Yuriana G Sánchez-Castro, Mónica Orozco-Carroll, Erick Mendoza-Schuster, Cecilio Velasco-BaronaAsociación Para Evitar la Ceguera en México I.A.P. Hospital “Dr Luis Sánchez Bulnes”, México City, MéxicoObjective: To evaluate the effectiveness of prophylactic administration of nepafenac 0.1% in maintaining mydriasis and in preventing postoperative macular edema following cataract surgery.Methods: This was a prospective, randomized, single-masked comparative study in 60 patients undergoing phacoemulsification cataract surgery. Patients were randomized to either the nepafenac or the control group. Nepafenac was administered 3 times daily 1 day before surgery and continued for 6 weeks. The control group received tobramycin-dexamethasone treatment only. Trans-operative mydriasis was measured before surgery, after nuclear emulsification, following cortex aspiration, and at the conclusion of surgery. Macular optical coherence tomography determined central foveal thickness (FT) and total macular volume (TMV) before surgery and at 2 and 6 weeks after surgery. All patients received tobramycin-dexamethasone for 2 weeks after surgery.Results: The difference in mean pupil size, at the end of surgery, between the control group (6.84 ± 0.93 mm) and the nepafenac group (7.91 ± 0.74 mm) was statistically significant (p < 0.001). There were no significant differences in FT values between the two groups at any time point; however, TMV at 2 and at 6 weeks was statistically significantly different (p < 0.001), with higher TMV in the control group.Conclusion: Prophylactic use of nepafenac was effective in reducing macular edema after cataract surgery and in maintaining trans-operative mydriasis.Keywords: nepafenac, mydriasis, macular edema, prophylactic, cataract surgeryKeywords
This publication has 38 references indexed in Scilit:
- Topical nepafenac in the treatment of diabetic macular edemaClinical Ophthalmology, 2008
- Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenacJournal of Cataract & Refractive Surgery, 2007
- In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJournal of Cataract & Refractive Surgery, 2007
- Surgical interventions for age-related cataractCochrane Database of Systematic Reviews, 2006
- Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: Pharmacokinetic-response curveJournal of Cataract & Refractive Surgery, 2006
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- A system for preoperative stratification of cataract patients according to risk of intraoperative complications: a prospective analysis of 1441 casesBritish Journal of Ophthalmology, 2004
- Prostaglandins and Cystoid Macular EdemaSurvey of Ophthalmology, 2002
- Efficacy of preoperative versus postoperative ketorolac tromethamine 0.5% in reducing inflammation after cataract surgeryJournal of Cataract & Refractive Surgery, 2000
- Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: II. In Vitro Bioactivation and Permeation of External Ocular BarriersInflammation, 2000